Opioid Long-Term Effectiveness: FDA Postmarket Trial Design Offers ‘Best Compromise’
Executive Summary
FDA advisory committee to consider proposed protocol to meet postmaketing requirement set a decade ago to determine risk of hyperalgesia following long-term use of ER/LA opioid analgesics. Initial trial was terminated in 2018 due to inability to recruit enough patients.
You may also be interested in...
Twilight Of The Opioids? Label Updates, Review Changes May Have Less Impact Than Shrinking Pipeline
Many prescribers don’t read drug labels, meaning they may not see the new warnings and recommendations in the immediate- and extended-release opioid labels, says Brandeis’ Kolodny. Meanwhile, as the Senate advances a bill that would allow comparative review of opioids, they make up a smaller amount of the drug development landscape.
No Vote, No Mandate? FDA Opioid Meeting Shows Limits Of Non-Voting Panels
US FDA Commissioner Califf has proposed that the agency move away from ‘gladiator votes’ that frame advisory committee meetings as a yes-or-no decision on a single question and instead emphasize the importance of the expert discussion and nuance of regulatory issues. The latest high-profile advisory committee review of a key opioid response issue shows the challenges with that approach.
Opioid Long-Term Effectiveness Trial Design Gets Middling Review From FDA Panel
Advisory committee agrees that a proposed study protocol could enroll patients but notes the outcome is foreseeable. Industry representative questions whether this postmarketing requirement is necessary.